LivaNova PLC (NASDAQ:LIVN) Shares Bought by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. lifted its position in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) by 17.7% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 621,959 shares of the company's stock after buying an additional 93,311 shares during the period. Charles Schwab Investment Management Inc. owned 1.15% of LivaNova worth $32,678,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of LIVN. Hexagon Capital Partners LLC raised its stake in LivaNova by 117.8% during the second quarter. Hexagon Capital Partners LLC now owns 684 shares of the company's stock worth $37,000 after purchasing an additional 370 shares during the period. Fifth Third Bancorp raised its stake in LivaNova by 97.1% during the second quarter. Fifth Third Bancorp now owns 674 shares of the company's stock worth $37,000 after purchasing an additional 332 shares during the period. Canada Pension Plan Investment Board acquired a new stake in shares of LivaNova in the second quarter worth $88,000. Central Pacific Bank Trust Division acquired a new stake in shares of LivaNova in the third quarter worth $178,000. Finally, TradeLink Capital LLC acquired a new stake in shares of LivaNova in the second quarter worth $208,000. Hedge funds and other institutional investors own 97.64% of the company's stock.

Analyst Ratings Changes

LIVN has been the subject of a number of recent analyst reports. Baird R W raised shares of LivaNova from a "hold" rating to a "strong-buy" rating in a report on Tuesday, September 17th. Needham & Company LLC reissued a "buy" rating and set a $75.00 price objective on shares of LivaNova in a report on Monday, November 25th. Robert W. Baird raised their price objective on shares of LivaNova from $66.00 to $72.00 and gave the stock an "outperform" rating in a report on Thursday, October 31st. The Goldman Sachs Group initiated coverage on shares of LivaNova in a report on Friday, October 4th. They set a "buy" rating and a $65.00 price objective for the company. Finally, Mizuho decreased their price objective on shares of LivaNova from $80.00 to $70.00 and set an "outperform" rating for the company in a report on Thursday, October 31st. One analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, LivaNova has an average rating of "Buy" and a consensus target price of $69.17.

LivaNova Stock Performance

NASDAQ:LIVN traded down $0.43 during mid-day trading on Wednesday, hitting $51.19. The stock had a trading volume of 492,082 shares, compared to its average volume of 608,748. The stock has a market capitalization of $2.78 billion, a price-to-earnings ratio of 122.90 and a beta of 0.98. The company has a 50 day simple moving average of $52.29 and a 200-day simple moving average of $51.95. LivaNova PLC has a 52 week low of $42.75 and a 52 week high of $64.47. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.